Remove research expertise-guide
article thumbnail

Artificial Intelligence & Antimicrobial Stewardship: An Interview With ChatGPT

IDStewardship

By exploring their expertise, experiences, and vision for the future, we aim to provide readers with valuable knowledge and inspiration to actively participate in the fight against AMR. Additionally, human expertise and judgment remain crucial in the interpretation and application of AI-generated insights in the context of AMR.

Vaccines 234
article thumbnail

Forge Biologics and Labcorp partner for gene therapies development

Pharmaceutical Technology

Gene therapy clients will gain access to coordinated scientific expertise, drug development services and AAV manufacturing capabilities, advancing the development of new gene therapies. This will improve accessibility to services for AAV-mediated gene therapy programmes.

102
102
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

MD Anderson and Xilis partner to expedite new cancer therapies development

Pharmaceutical Technology

The preclinical research deal will combine the MicroOrganoSphere (MOS) platform of Xilis with the expertise of MD Anderson for advancing new therapies development and cancer research. The MOS platform enables translational research on micro-tumours derived from patients with new capabilities.

article thumbnail

Ginkgo Bioworks partners with WARF for new GD2 CAR T-cell therapies

Pharmaceutical Technology

Ginkgo Bioworks (Ginkgo) and the Wisconsin Alumni Research Foundation (WARF) have collaborated to discover next-generation GD2 CAR T-cell therapies to treat solid tumours. Ginkgo will partner with researchers from Wisconsin-Madison to discover new and improved GD2 CAR designs with improved persistence, fitness and proliferation.

105
105
article thumbnail

Regeneron and Sonoma Biotherapeutics partner to develop T cell therapies

Pharmaceutical Technology

The two companies will together research and develop T cell therapies for Crohn’s disease and ulcerative colitis, as well as two other undisclosed indications. The companies will co-fund research and development for all products and split the future commercial expenses and profits equally.

98
article thumbnail

Sanofi and Queensland collaborate to build $190m research facility

Pharmaceutical Technology

Sanofi has signed an agreement with the Queensland Government in Australia to establish a $190m (A$280m) research facility in Brisbane. The hub will connect Queensland scientists with the teams at Sanofi’s mRNA Centre of Excellence in the US and France, putting them at the front of international vaccine development and biomedical research.

article thumbnail

Umoja and IASO partner to develop therapies for haematological malignancies

Pharmaceutical Technology

Umoja Biopharma has signed a research agreement with IASO Biotherapeutics (IASO Bio) to develop off-the-shelf therapies for haematological malignancies. In the initial stage, the partnership will focus on acute myeloid leukaemia (AML) to boost accessibility to patients.

110
110